Fennec Pharmaceuticals Inc (NASDAQ:FENC) Reports Mixed Q2 2025 Earnings with Revenue Slight Miss and Wider-Than-Expected Loss

Fennec Pharmaceuticals Inc (NASDAQ:FENC) reported its second-quarter 2025 financial results, revealing mixed performance relative to analyst expectations. The company posted total net revenues of $9.7 million, slightly below the consensus estimate of $9.71 million. Meanwhile, its earnings per share (EPS) came in at -$0.11, significantly wider than the anticipated -$0.0367.

Key Financial Highlights

• Revenue: Reported $9.65 million in Q2 2025, narrowly missing estimates by approximately 0.6%.
• EPS: Posted a loss of $0.11 per share, underperforming expectations by nearly 200%.
• Market Reaction: The stock showed modest pre-market movement, rising just under 1%, while it has gained 11.6% over the past week and 8.3% over the last two weeks.

Business Update & Growth Drivers

The company highlighted continued expansion in its commercial footprint for PEDMARK®, its FDA-approved therapy to reduce cisplatin-induced hearing loss in pediatric cancer patients. Key takeaways from the press release include:

• New Account Growth: The company reported double-digit growth in new accounts, including increased adoption in large community practices and academic centers.
• Sales Strategy: Fennec emphasized its targeted sales approach and enhanced patient support services as contributors to sustained demand.

Forward-Looking Expectations

Analysts project full-year 2025 revenue at $47.94 million, with Q3 estimates set at $13.59 million. The company did not provide explicit guidance in its press release, leaving investors to rely on external forecasts. Given the slight revenue miss and deeper-than-expected losses, the market’s muted reaction suggests investors may be weighing long-term commercial execution against near-term financial performance.

For a deeper dive into Fennec’s earnings and analyst estimates, visit the FENC earnings page.

Disclaimer: This article is for informational purposes only and does not constitute investment advice.